PROXIME

Proxime builds a device to make it faster and easier to alter cells with beneficial DNA. The device forces the viral vector and the cells into direct contact by organizing them into a space as thin as human hair. That means far less of the costly vector is needed. Proxime’s device can create 1 billion altered cells at a time, six times faster than conventional approaches and with one-fourth the amount of vector. The result will be more accessible, affordable gene therapy.

#SimilarOrganizations #Financial #More

PROXIME

Industry:
Biotechnology Genetics Life Science

Founded:
2021-01-01

Status:
Active

Total Funding:
67.09 K USD


Similar Organizations

kolibri-logo

KOLIBRI

Next-generation cell-culture platform to unlock biologics manufacturing, starting with gene therapies

kytopen-logo

Kytopen

Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.

navrogen-logo

Navrogen

Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.

Investors List

georgia-research-alliance_image

Georgia Research Alliance

Georgia Research Alliance investment in Grant - Proxime

georgia-research-alliance_image

Georgia Research Alliance

Georgia Research Alliance investment in Grant - Proxime

More informations about "Proxime" on Search Engine